Brineura is recombinant human tripeptidyl peptidase 1 (TPP1) replacement enzyme to slow loss of walking ability in symptomatic pediatric patients aged 3 years and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2). Brineura is infused into the cerebrospinal fluid (CSF) via an intraventricular access device implanted in the patient’s head. It is administered once every 2 weeks.

If you have a Hayes login, click here to view the full report on the Knowledge Center.